Dublin, Nov. 01, 2019 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease - Markets, Strategies, Trends, Volume & Price Forecasts by Pathogen & by Country - With Multiplex and Point of Care Market Analysis, Executive Guides and Customization 2020 to 2024" report has been added to ResearchAndMarkets.com's offering.

Multiplex testing threatens existing infectious disease practice. The microbiology lab may disappear.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth.

A market that just keeps on growing. In spite of the steady decline of disease prevalence, the diagnostic sector keeps growing. Find out why in the informative report; and find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics.

Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

• Multiplex testing
• Emerging economies and global prosperity
• Biotechnology advances in genetics
• Pathogen evolution
• Climate change
• Globalization
• The rise of rapid testing

Exciting technical developments especially in the seesaw between sequencing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2016 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Key Topics Covered

1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Market Analysis by Disease
2.1 HIV - Human Immunodeficiency Virus (AIDS)
2.1.1 Virology
2.1.1.1 Classification
2.1.1.2 Structure and genome
2.1.1.3 Tropism
2.1.1.4 Replication cycle
2.1.1.5 Genetic variability
2.1.2 Diagnosis
2.1.3 Testing
2.1.3.1 Antibody tests
2.1.3.2 Point of Care Tests (POCT)
2.1.3.4 Antigen Tests
2.1.3.5 Nucleic acid-based tests (NAT)
2.1.3.6 Other tests used in HIV treatment
2.1.4 Market Opportunity Analysis
2.2 HBV - Hepatitis B
2.2.1 Virology
2.2.1.1 Genome
2.2.1.2 Pathogenesis
2.2.1.3 Hepatitis B virus replication
2.2.1.4 Serotypes and genotypes
2.2.2 Mechanisms
2.2.3 Diagnosis
2.2.4 Market Opportunity Analysis
2.3 HCV - Hepatitis C
2.3.1 Taxonomy
2.3.2 Structure
2.3.2.2 Genome
2.3.3 Molecular biology
2.3.4 Replication
2.3.5 Genotypes
2.3.5.1 Clinical importance
2.3.6 Market Opportunity Analysis
2.4 HPV - Human papillomavirus
2.4.1 Virology
2.4.1.1 E6/E7 proteins
2.4.1.2 Role in cancer
2.4.1.3 E2 research
2.4.1.4 Latency period
2.4.1.5 Clearance
2.4.2 Diagnosis
2.4.2.1 Cervical testing
2.4.2.2 Oral testing
2.4.2.3 Testing men
2.4.2.4 Other testing
2.4.3 Market Opportunity Analysis
2.5 Influenza
2.5.1 Virology
2.5.1.1 Types of virus
2.5.1.2 Influenzavirus A
2.5.1.3 Influenzavirus B
2.5.1.4 Influenzavirus C
2.5.1.5 Structure, properties, and subtype nomenclature
2.5.1.6 Replication
2.5.2 Testing
2.5.2.1 Advantages/Disadvantages of Molecular Assays
2.5.3 Market Opportunity Analysis
2.6 CTGC - Chlamydia/Gonorhea
2.6.1 Gonorrhea
2.6.1.1 Diagnosis
2.6.1.2 Screening
2.6.2 Chlamydia
2.6.2.1 Diagnosis
2.6.2.2 Screening
2.6.3 Testing
2.6.3.1 Nucleic acid amplification tests (NAATs)
2.6.3.2 Performance of NAAT Tests
2.6.4 Market Opportunity Analysis
2.7 Tuberculosis
2.7.1 Mycobacteria
2.7.2 Diagnosis
2.7.2.1 Active tuberculosis
2.7.2.2 Latent tuberculosis
2.7.3 Epidemiology
2.7.4 Molecular Diagnostic Tests
2.7.5 Market Opportunity Analysis
2.8 MRSA - Methicillin-resistant Staphylococcus aureus
2.8.1 Diagnosis
2.8.2 FDA Approved Molecular Tests
2.8.3 Market Opportunity Analysis
2.9 VRE - Vancomycin-resistant Enterococcus
2.9.1 FDA Approved MDx Tests for VRE
2.9.2 Market Opportunity Analysis
2.10 Blood Screening
2.10.1 Collection and Testing
2.10.2 FDA Approved Multiplex Assays
2.10.3 Market Opportunity Analysis

3. Industry Overview
3.1 Industry Participants
3.1.1 IVD Supplier
3.1.2 Independent lab specialized/esoteric
3.1.3 Independent lab national/regional
3.1.4 Independent lab analytical
3.1.5 Public National/regional lab
3.1.6 Hospital lab
3.1.7 Physician lab
3.1.8 Audit body
3.2 The Clinical Laboratory Market Segments
3.2.1 Traditional Market Segmentation
3.2.2 Laboratory Focus and Segmentation
3.3 Industry Structure
3.3.1 Hospital Testing Share
3.3.2 Economies of Scale
3.3.2.1 Hospital vs. Central Lab
3.3.3 Physician Office Lab's
3.3.4 Physician's and POCT
3.4 Profiles of Key MDx Companies

• Abbott Diagnostics
• Accelerate Diagnostics
• Ador Diagnostics
• Akonni Biosystems
• Alveo Technologies
• Applied BioCode
• Atlas Genetics
• Aus Diagnostics
• BD Diagnostics
• Beckman Coulter
• Bosch Healthcare Solutions GmbH
• Cepheid
• Chembio
• Curetis
• Diagenode Diagnostics
• DiaSorin
• Eiken Chemical
• Genedrive
• GenePOC Diagnostics
• GenMark Dx
• Grifols
• Hologic
• Illumina
• Inflammatix
• Janssen Diagnostics
• Karius
• Lexagene
• Luminex
• Mbio Diagnostics
• Meridian Bioscience
• Mesa Biotech
• Mobidiag
• Nanomix
• Oxford Nanopore Technologies
• Panagene
• Primerdesign
• Prominex
• Qiagen
• Quantumdx
• Quidel
• Seegene
• Siemens Healthineers
• T2 Biosystems
• Thermo Fisher
• Veramarx
• XCR Diagnostics

4. Market Trends
4.1 Factors Driving Growth
4.1.1 New Genotypes Creating New Markets
4.1.2 Aging Population a Boon for All Diagnostics
4.1.3 Developing World Driving ID Dx Growth
4.1.4 Point of Care - Why Centralization is Losing Steam
4.1.5 Self Testing
4.1.6 The Need for Speed
4.2 Factors Limiting Growth
4.2.1 Lower Costs
4.2.2 Infectious Disease is Declining
4.2.3 Wellness Hurts
4.2.4 Economic Growth improves Living Standards
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 The Shrinking Machine.
4.3.2 Multiplex, Point of Care and The Speed Factor
4.4 Diagnostic Technology Development
4.4.1 The Sepsis Testing Market - A New Direction?
4.4.2 POCT/Self Testing as a Disruptive Force
4.4.3 The Genetics Play - One Test for All Known Infections
4.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

5. Molecular Dx - Infectious Disease Recent Developments

• Recent Developments - Importance and How to Use This Section
• Importance of These Developments
• How to Use This Section

• Ares Genetics signs R&D agreement with leading global IVD corporation
• Cell-Free DNA Used for Infectious Disease Testing
• One BioMed Raises $5M
• FDA grants Qiagen clearance for syndromic testing system
• iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assays
• Researchers Launch CRISPR Dx Firm Sherlock Biosciences
• Israel's BATM to Invest up to $30M in Ador Diagnostics
• Superbug Test from Mobidiag Gets CE Mark
• Akonni Biosystems Submits Multiplex Diagnostics System to FDA
• Mesa Biotech RSV Test Wins CE Mark
• Karius Test to Be Available in Brazil
• Panagene's STD kit gains Approval
• Startup Prominex Raises $4M in Series A1
• GenePOC's Investment Validated by Medicare Decision
• GenePOC launches its GenePOC CDiff test in Canada
• NYU researchers adapt HIV test to Zika virus
• GA-EMS receives diagnostic device contract
• Biocartis & Immunexpress Sign Partnership for Sepsis
• PerkinElmer to Acquire Euroimmun for $1.3B
• Alveo Closes Financing to Create Accessible Diagnostics Devices
• Siemens Healthineers completes takeover of Fast Track Diagnostics
• Sekisui Diagnostics Enters Strategic Alliance with Mesa Biotech Inc
• Chembio and FIND to Develop Point-of-Care Multiplex Test
• Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test
• Alere bags FDA nod for rapid flu diagnostic
• FDA approves tests of tick-borne disease to protect blood supply
• Qiagen Trichomonas Assay Gets CE Mark
• Vela Diagnostics HSV Test Gets FDA Clearance
• QIAGEN enters into agreement to acquire STAT-Dx
• Bruker to Acquire Majority Stake in Infectious Disease MDx Firm Hain
• Applied BioCode's Syndromic Gastrointestinal Pathogen Panel Approved by the FDA
• Ares Genetics to develop AI diagnostic test for infectious diseases
• FDA Considers Guidelines for NGS-Based Infectious Disease Diagnostics

6. Country Market Sizes - North America
6.1 United States of America
6.2 Canada

7. Country Markets - Europe
7.1 France
7.2 Germany
7.3 United Kingdom
7.4 Spain
7.5 Italy
7.6 Switzerland
7.7 Czech Republic
7.8 Belgium
7.9 Russia
7.10 Remainder of Europe and Former Soviet Union

8. Country Markets - Asia Pacific
8.1 China
8.2 Japan
8.3 South Korea
8.4 India
8.5 Australia
8.6 Rest of Asia Pacific

9. Country Markets - Latin America, Africa & The Middle East
9.1 Brazil
9.2 Mexico
9.3 Remainder of Latin America
9.4 Africa & The Middle East

10. Global Market Summary
10.1 Global Market
10.1.1 HIV - Volumes, Prices, Revenues
10.1.2 HBV - Volumes, Prices, Revenues
10.1.3 HCV - Volumes, Prices, Revenues
10.1.4 HPV - Volumes, Prices, Revenues
10.1.5 FLU - Volumes, Prices, Revenues
10.1.6 CHGC - Volumes, Prices, Revenues
10.1.7 Tb - Volumes, Prices, Revenues
10.1.8 MRSA - Volumes, Prices, Revenues
10.1.9 VRE - Volumes, Prices, Revenues
10.1.10 Screening/Other - Volumes, Prices, Revenues

Appendices
I. United States Medicare System: 2019 Clinical Laboratory Fees Schedule
II. FDA Approved Human Genetic Tests
III. FDA Approved Microbial Tests
IV. FDA Approved Pharmacogenomics Tests

For more information about this report visit https://www.researchandmarkets.com/r/dr03us

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900